Ablynx Drug Fails Again in Mid-Stage Trial

For the second time Ablynx’s anti-IL-6R Nanobody, vobarilizumab has failed to pass muster. This morning Belgium-based company said vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients. Source: BioSpace

Read More

ImmunoGen Stock Climbs on Positive Ovarian Cancer Data

ImmunoGen, released positive efficacy and tolerability data from its FORWARD II trial of its mirvetuximab soravtansine in combination with Merck’s Keytruda in platinum-resistant epithelial ovarian cancer (EOC). Shares jumped almost 12 percent in premarket trading. Source: BioSpace

Read More

Akebia Announces $85M Public Offering

Akebia Therapeutics, a kidney disease company, announced plans to offer and sell about $85 million of its common stock in an underwritten public offering. Source: BioSpace

Read More